IDEXX Laboratories, Inc. $IDXX Stake Cut by Vantage Investment Partners LLC

Vantage Investment Partners LLC cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,766 shares of the company’s stock after selling 2,077 shares during the quarter. IDEXX Laboratories comprises approximately 1.6% of Vantage Investment Partners LLC’s investment portfolio, making the stock its 21st biggest position. Vantage Investment Partners LLC’s holdings in IDEXX Laboratories were worth $27,032,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $25,000. Elevation Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares during the period. Pension & Wealth Management Advisors Inc. purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at about $29,000. Arlington Trust Co LLC increased its position in IDEXX Laboratories by 46.3% during the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after purchasing an additional 19 shares during the last quarter. Finally, Pin Oak Investment Advisors Inc. acquired a new stake in IDEXX Laboratories during the second quarter worth about $49,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.3%

Shares of NASDAQ:IDXX opened at $562.91 on Thursday. The company has a market capitalization of $44.35 billion, a price-to-earnings ratio of 39.59 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98. The business has a 50-day moving average price of $533.89 and a 200 day moving average price of $575.65. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on IDXX shares. JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research note on Friday, October 16th. KeyCorp initiated coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They issued a “sector weight” rating for the company. Barclays dropped their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Citigroup raised their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Nine research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $727.69.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.